Home › NDC Lookup › Drug shortages › Amino Acid Injection

This page is curated, coded, and maintained by

Compiled from public FDA (openFDA) and CMS (Medicaid) data sources. Editorial policy

Amino Acid Injection shortage

Amino Acid Injection is currently listed in shortage by the FDA. The FDA lists 16 affected products. The reported reason: Shortage of an active ingredient; Shortage of an inactive ingredient component. This page was last refreshed from FDA data on Oct 2, 2026.

Current ⚠ Supply risk: Low Gastroenterology 16 products 3 manufacturers 2,125 days · 5.8 yr First posted Dec 8, 2020 Updated Sep 22, 2026
Here’s the bottom line

Some strengths of amino acid injection are in short supply, including the preservative-free Aminosyn-PF 7% and 10% versions, due to shortages of active and inactive ingredients lasting over a year. Several other strengths — including Aminosyn II, TrophAmine, Clinisol, and Premasol products — still have available sources, though Baxter's recovery for its affected products is not expected until December 2026.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
16
Affected NDCs
3
Reporting manufacturers
3/3
Reporting mfrs supplying
8/10
Affected strengths / sizes supplied
19%
NDCs unavailable
2,125
Days in shortage
59,472
Medicaid Rx (2026)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Oct 2, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Amino Acid Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
16 NDCs
Available 13 Unavailable 3
Affected strengths / sizes still supplied
Among manufacturers reporting this shortage
8/10 strengths / sizes
Sourceable 8 No supply 2
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
3/3 makers
With supply 3
Other manufacturers
We couldn’t automatically confirm other manufacturers of Amino Acid Injection that aren’t reporting a shortage. Ask your pharmacist whether a different manufacturer or strength can be ordered.
Shortage timeline
  1. Sep 22, 2026
    Currently in shortage
    16 of 16 products affected.
  2. Sep 17, 2026
    FDA refreshed this shortage record
    9 products updated.
  3. Sep 16, 2026
    FDA refreshed this shortage record
    4 products updated.
  4. Dec 8, 2020
    First reported to the FDA
    16 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 3 NDCS click to expand
Status NDC / product Strength / size Availability Related information Reason
Current Plenamine, Injection, 0.15 (NDC 0264-4500-05) NDC 00264-4500-05 — Available — —
Current Plenamine, Injection, 0.15 (NDC 0264-4500-00) NDC 00264-4500-00 — Available — —
Current TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10) NDC 00264-1933-10 — Available — —
Manufacturer: Baxter Healthcare 📞 888-229-0001 9 NDCS click to expand
Status NDC / product Strength / size Availability Related information Reason
Current Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06) NDC 00338-0502-06 — Available — —
Current Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06) NDC 00338-1130-06 — Available — —
Current Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04) NDC 00338-1130-04 — Available — —
Current Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 NDC 00338-0644-06 — Available — —
Current Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 NDC 00338-0644-04 — Available — —
Current Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03) NDC 00338-1130-03 — Available — —
Current Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03) NDC 00338-0502-03 — Available — —
Current Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0 NDC 00338-0644-03 — Unavailable Estimated recovery: December 2026 Shortage of an inactive ingredient component
Current PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg NDC 00338-0499-06 — Available — —
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 4 NDCS click to expand
Status NDC / product Strength / size Availability Related information Reason
Current Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03) NDC 00990-4178-03 — Unavailable Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Shortage of an active ingredient
Current Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05) NDC 00990-4179-05 — Unavailable Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. Shortage of an active ingredient
Current Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17) NDC 00990-7172-17 — Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. —
Current Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17) NDC 00990-7171-17 — Available This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. —

These rows are manufacturer reports to the FDA for Amino Acid Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Amino Acid Injection? options further down this page.

Why is Amino Acid Injection in shortage?

A note from Dr. Brian Staiger, PharmD

Amino Acid Injection is on the shortage list for two separate reasons depending on the manufacturer and product involved. For Baxter Healthcare, one version of their Travasol injection is currently unavailable because of a shortage of an inactive ingredient — meaning one of the non-active components needed to make that specific product isn't available in enough supply right now. Baxter estimates that particular Travasol product should be back around December 2026. Other Baxter products in this family — including Clinisol 15%, Prosol 20%, Premasol 10%, and other Travasol versions — are still available.

For Otsuka/ICU Medical, two preservative-free versions — Aminosyn-PF 7% and Aminosyn-PF 10% — are currently unavailable because of a shortage of an active ingredient (one of the actual amino acids needed to make the product). Unfortunately, there is no estimated recovery date yet for either of those — it's listed as "to be determined." Their Aminosyn II 10% and Aminosyn II 15% products, on the other hand, are still available. B. Braun's products in this category are also currently listed as available.

FDA reason code(s): Shortage of an active ingredient; Shortage of an inactive ingredient component

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Amino Acid Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Amino Acid Injection?

A note from Dr. Brian Staiger, PharmD

Amino Acid Injection is currently on the FDA shortage list. This is a large family of related IV nutrition products, and most forms still have a supplier, so I want to help you find the one that matches what you take.

Two specific forms have no available source right now: Aminosyn-PF 10% and Aminosyn-PF 7%. Many other forms remain available from their makers, including Aminosyn II 15% and 10%, TrophAmine 10%, Premasol 10%, Clinisol 15%, PROSOL 20%, and several Travasol presentations. One Travasol NDC is listed as unavailable with an estimated recovery of December 2026, while other Travasol listings show as available.

The FDA reports the cause as a shortage of an active ingredient and of an inactive ingredient component. All three manufacturers on this record are still reporting some available supply, which is encouraging, though this situation has lasted over a year.

Here is what I suggest:

  • Do not stop, skip, or change your dose on your own.
  • If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other manufacturers.
  • If your exact form is unavailable or discontinued, ask your prescriber or pharmacist about options, such as a different strength or a clinician-chosen alternative.
  • Manufacturer contact numbers are listed on this page; pharmacies usually handle those calls.

This reflects national, manufacturer-reported data and may not match your local pharmacy's stock.

If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Therapeutic equivalents & pricing 4 productsclick to expand

Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Plenamine 1.18 g/100mL; 1.04 g/100mL; 1.04 g/100mL; 960 mg/100mL; 749 mg/100mL; 749 mg/100mL; 749 mg/100mL; 250 mg/100mL; 2.17 g/100mL; 1.47 g/100mL; 1.0NDC 00264-4500-05 B. 2000 ml — — FDA listed
Clinisol 1.18 g/100mL; 1.04 g/100mL; 1.04 g/100mL; 960 mg/100mL; 894 mg/100mL; 749 mg/100mL; 749 mg/100mL; 749 mg/100mL; 250 mg/100mL; 2.17 g/100mL; 1NDC 00338-0502-03 Baxter 500 ml — — FDA listed
Plenamine 1.18 g/100mL; 1.04 g/100mL; 1.04 g/100mL; 960 mg/100mL; 749 mg/100mL; 749 mg/100mL; 749 mg/100mL; 250 mg/100mL; 2.17 g/100mL; 1.47 g/100mL; 1.0NDC 00264-4500-00 B. 1000 ml — — FDA listed
TrophAmine .82 g/100mL; 1.4 g/100mL; 1.2 g/100mL; .34 g/100mL; .48 g/100mL; .42 g/100mL; .2 g/100mL; .78 g/100mL; .024 g/100mL; .48 g/100mLNDC 00264-1933-10 B. 500 ml — — FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Amino Acid Injection — that fall in the same broad treatment class (parenteral amino acid solutions and combinations) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Amino Ac 3%/Electrolyte/Glycer Amino Acids 10 % Parenteral Amino Acid 15% No.1 Parenteral Amino Acid 10% No.4 Amino Acids 8 % Amino Acid 8 % In D14W Amino Acid 8 % In D10W Amino Acid 6 % In 5 % Dextrose Amino Ac 8 %/D14W/Electrolytes Amino Ac 8 %/D10W/Electrolytes Parenteral Amino Acid 20% No.1 Parenteral Amino Acid 15% No.5 Parenteral Amino Acid 10% No.6 Aa 4.25 % No.1/Dextrose 5 % Aa 4.25 % No.1/Dextrose 10 %

Identity & classification

GCN Seq No 079645
GCN 46184
HICL code 045683
Ingredient (HICL) Parenteral Amino Acid 15% No.6
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C9
Therapeutic class — intermediate (HIC2) Carbohydrates And/Or Proteins (Continued 1)
HIC3 code C9C
Therapeutic class — specific (HIC3) Parenteral Amino Acid Solutions And Combinations
AHFS code 40:20.00.00
AHFS class Caloric Agents
FDB label name PLENAMINE 15% SOLUTION
FDB brand name Plenamine
Legend status F — Federal legend — prescription drug or device
GPI-1480302010102060
GPI classPlenamine
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other gastroenterology shortages

Mesalamine Capsule, Extended Release To Be Discontinued · 3 NDCS Polyethylene Glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, And Potassium Chloride Oral Solution To Be Discontinued · 1 NDC Aprepitant Oral Powder For Suspension To Be Discontinued · 1 NDC Fosaprepitant Dimeglumine Injection To Be Discontinued · 1 NDC Palonosetron Hydrochloride Injection To Be Discontinued · 1 NDC Omeprazole Delayed Release Capsule To Be Discontinued · 10 NDCS

Amino Acid Injection shortage FAQs

Is Amino Acid Injection in shortage?
Yes — the FDA currently lists Amino Acid Injection in shortage (status: “Current”, first reported Dec 8, 2020). 16 of 16 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Why is Amino Acid Injection in shortage?
The manufacturer-reported reason on file with the FDA: Shortage of an active ingredient; Shortage of an inactive ingredient component.
Which products are affected?
Plenamine, Injection, 0.15 (NDC 0264-4500-05) (NDC 00264-4500-05); Plenamine, Injection, 0.15 (NDC 0264-4500-00) (NDC 00264-4500-00); TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10) (NDC 00264-1933-10). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Amino Acid Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
What should I do if I take Amino Acid Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Amino Acid Injection shortage?

Ask a pharmacist about this shortage →

View Amino Acid Injection on the FDA drug-shortage database →

How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages